SLC5A2 and ischemic stroke: To investigate the in vivo pretreatment effect of a selective SGLT2 inhibitor luseogliflozin on the acute phase of ischemic stroke, non-diabetic adult male C57BL/6JJcl mice were treated with or without 0.0001% luseogliflozin mixed with a regular diet (equivalent to 0.1 mg/kg/day) for 2 weeks and then subjected to pMCAO (Fig. 1a).